BioReference Laboratories OnKoSight Advanced

Opko Health's BioReference Laboratories announced the launch of its next-generation sequencing assay OnKoSight Advanced, which enables DNA mutational profiling of tumor samples. The test, developed by BioReference's specialty oncology division GenPath, offers targeted gene content aligned with recent National Comprehensive Cancer Network and World Health Organization guidelines. The panels include key biomarkers, such as tumor mutation burden and tumor-only microsatellite, and are tumor-type specific. They are also "optimized to exclude extraneous gene content," the company said.